Countries report very different success in moving people from a chronic hepatitis C diagnosis into treatment. In the 91 WHO observations actually dated 2024, the median share of diagnosed people who had initiated HCV treatment is 28.1%, while the simple unweighted mean is 39.9%. Thirty-five observations are below 20%, but 16 are at 80% or above. Azerbaijan, the Cook Islands, Ghana, Sri Lanka, Maldives and the United Republic of Tanzania report 100% in the common-year subset.
The denominator is essential. This indicator does not measure treatment among everyone infected with hepatitis C. It asks what share of people already diagnosed with chronic HCV infection have initiated treatment. A country can therefore report a high treatment rate among diagnosed patients while still having an important diagnosis gap. The measure is best read as one step in the hepatitis C care cascade rather than as a complete score for national HCV control.
Table of Contents
The indicator measures treatment initiation among people already diagnosed with chronic HCV
The WHO indicator metadata defines the HCV component as the percentage of people diagnosed with chronic hepatitis C infection who have been initiated on treatment. The numerator is the number of diagnosed people who have initiated HCV treatment, and the denominator is the number of people living with chronic HCV who have been diagnosed. Programme monitoring, clinical records, testing records and laboratory registers can contribute to these figures.
That definition separates this measure from several familiar hepatitis statistics. It is not HCV prevalence, not diagnosis coverage among all infected people, and not the share of all infected people who have ever been treated. It also does not directly tell us whether a person completed a regimen or achieved sustained virologic response. Its narrower question is whether a diagnosed chronic HCV case crossed the next threshold and began treatment.
The treatment step matters because modern hepatitis C therapy is highly effective. The WHO hepatitis C fact sheet states that direct-acting antivirals can cure more than 95% of people with HCV infection. WHO also notes that there is currently no effective vaccine against hepatitis C. Finding infections and linking diagnosed patients to curative treatment are therefore central parts of reducing long-term complications such as cirrhosis and liver cancer.
The 2024 median is 28.1%, well below the unweighted mean of 39.9%
Restricting the comparison to the 91 observations dated 2024 removes the main reference-year mismatch. The median is 28.1% and the simple unweighted mean is 39.9%. The 11.8 percentage-point gap between those two summary statistics shows how strongly the high-coverage tail pulls the mean upward. Neither number is a population-weighted global HCV treatment rate; each country or area contributes one equally weighted observation.
The distribution is concentrated toward the lower end. Thirty-five observations are below 20%, 19 are from 20% to under 40%, 12 are from 40% to under 60%, nine are from 60% to under 80%, and 16 are in the 80–100% band. That means 25 countries or areas reach at least 60%, while 35 remain below 20%. The synchronized dataset is therefore not centered around a single typical treatment level.
Six 2024 observations are reported at 100%
Azerbaijan, the Cook Islands, Ghana, Sri Lanka, Maldives and the United Republic of Tanzania each report 100% in 2024. Egypt follows at 96.7%, Cambodia at 93.0%, the occupied Palestinian territory including east Jerusalem at 91.6%, Uruguay at 90.7% and Guyana at 90.2%. Malaysia is at 86.0%, Ecuador 84.0%, Eritrea 83.3%, Indonesia 81.8% and Georgia 80.9%.
| Country or area | HCV treatment among diagnosed people, 2024 |
|---|---|
| Azerbaijan | 100.0% |
| Cook Islands | 100.0% |
| Ghana | 100.0% |
| Sri Lanka | 100.0% |
| Maldives | 100.0% |
| United Republic of Tanzania | 100.0% |
| Egypt | 96.7% |
| Cambodia | 93.0% |
| Occupied Palestinian territory, including east Jerusalem | 91.6% |
| Uruguay | 90.7% |
| Guyana | 90.2% |
| Malaysia | 86.0% |
A reported value of 100% should be interpreted within the denominator of this indicator. It indicates that the reported number of diagnosed chronic HCV cases initiating treatment matches, or effectively matches, the diagnosed population used in the calculation. It does not establish that every person infected with HCV in the country has been diagnosed, that reinfection is impossible, that every course was completed, or that cure was confirmed in every treated patient.
Thirty-five 2024 observations are below 20%
At the lower end, Lesotho and Eswatini are each at 0.90%, Botswana at 0.92% and Qatar at 1.19%. The Federated States of Micronesia reports 3.00%, Madagascar 3.63%, Vanuatu 3.91%, Saudi Arabia 5.67%, Iraq 6.16%, Chad 6.41%, Papua New Guinea 6.73% and Gabon 6.82%. With 35 observations below 20%, the low-coverage tail is a substantial part of the 2024 distribution rather than a handful of isolated outliers.
| Country or area | HCV treatment among diagnosed people, 2024 |
|---|---|
| Lesotho | 0.90% |
| Eswatini | 0.90% |
| Botswana | 0.92% |
| Qatar | 1.19% |
| Micronesia (Federated States of) | 3.00% |
| Madagascar | 3.63% |
| Vanuatu | 3.91% |
| Saudi Arabia | 5.67% |
| Iraq | 6.16% |
| Chad | 6.41% |
| Papua New Guinea | 6.73% |
| Gabon | 6.82% |
The dataset does not contain the variables needed to assign a cause to a low value. Referral systems, medicine procurement, treatment eligibility rules, patient follow-up, service accessibility and reporting completeness can all matter, but the map does not measure those mechanisms. The correct use of the map is to identify where the reported transition from diagnosis to treatment is low and then look for separate country-specific evidence before drawing causal conclusions.
Large and populous countries do not converge on one treatment level
Among notable 2024 observations, Indonesia is at 81.77%, Mexico 72.84% and Pakistan 64.93%. South Africa is at 28.96%, Nigeria 22.00%, Bangladesh 18.24%, the Philippines 11.86% and Ethiopia 11.35%. These percentages do not rank countries by the absolute number of people treated. A country with a large diagnosed HCV population can have a high percentage and still need to treat many people, while a smaller country can reach the same percentage with far fewer patients.
Several very large countries, including the United States, China and India, do not have a row in this 96-observation extract. Their absence is not a zero and should not be interpreted as an absence of treatment. The same rule applies to the gray areas on the map: gray means that no retained country observation was available in this dataset, not that the treatment rate is 0%.
The latest-value map mixes five observations from years other than 2024
Ninety-one of the 96 latest retained observations are dated 2024, so the year alignment is relatively strong but not perfect. Brazil is newer, at 82.61% in 2025. Canada is 90.78% in 2023, the Republic of Korea 83.74% in 2023, Australia 9.50% in 2023, and Japan 33.10% in 2021. A ranking that silently mixed all five with 2024 observations would combine different reference periods.
The map therefore hatches those five countries and the common-year statistics deliberately exclude them. Brazil’s 82.61% is shown on the latest-value map but is not inserted into the 2024 ranking. Canada, Korea, Australia and Japan are handled the same way. This distinction between “latest available” and “same year” is important whenever national health reporting schedules differ.
High treatment among diagnosed people does not guarantee high diagnosis coverage
The hepatitis C care cascade contains at least two separate coverage questions: how many infected people have been diagnosed, and how many diagnosed people have started treatment. If only a small fraction of infected people have been diagnosed, a high treatment percentage among that diagnosed subset can coexist with much lower treatment coverage across everyone infected. Conversely, broader diagnosis can enlarge the denominator and make the treatment-linkage challenge more visible.
WHO therefore publishes diagnosis and treatment indicators separately in its chronic viral hepatitis data. Hepatitis C has no effective vaccine, but it can usually be cured with antiviral medicines. Progress toward elimination depends on finding infections, confirming chronic infection and then moving people into effective treatment. This map focuses only on that last transition among people already diagnosed.
The geographic pattern is descriptive, not an explanation of health-system performance
Very high and very low values can occur within the same broad region. Egypt is at 96.7%, while Qatar is at 1.19% and Saudi Arabia at 5.67%. In Africa, Ghana and the United Republic of Tanzania are reported at 100%, while Lesotho and Eswatini are at 0.90%. In Asia, Sri Lanka is 100%, Cambodia 93.0% and Indonesia 81.8%, while the Philippines is 11.9%. A continental label is therefore too coarse to describe the country-level pattern.
Those contrasts should not be treated as proof of a particular policy effect. Countries differ in their diagnosed populations, reporting systems, reference years, programme design and the completeness of monitoring data. The map is useful for locating large reported gaps and for deciding where more detailed country research is warranted. It is not, by itself, a league table of clinical quality or a causal evaluation of national hepatitis policy.
Data source and calculation method
The statistical source is the WHO Global Health Observatory indicator HEPATITIS_HCV_TREATMENT_PERDIAGNOSED_PER100. The observations are available through the WHO GHO OData API, while the numerator, denominator, rationale and data-source notes are documented in the WHO indicator metadata. The unit is percent, and one latest preferred non-disaggregated observation is retained for each country or area in the dataset.
The latest-value map uses all 96 retained rows and separately marks the five observations not dated 2024. The median, mean, grouped distribution and ranking tables use only the 91 rows whose year equals 2024. Missing observations are never replaced with zero. ISO-3 codes are joined to a low-resolution world boundary layer, so Andorra, Cook Islands, Comoros, Cabo Verde, Cayman Islands, Micronesia, Maldives, Singapore and Seychelles remain in the statistical calculations even when they do not appear as distinct polygons at this scale.
Decimal values are preserved from the source, but close decimal rankings should not be overinterpreted. A difference such as 28.09% versus 28.96% does not establish a meaningful difference in clinical performance. The strongest signal in this dataset is the much wider separation between the large below-20% group and the countries reporting 80% or more treatment initiation among diagnosed people.
Frequently Asked Questions
What does the chronic HCV treatment rate among diagnosed people measure?
It measures the percentage of people diagnosed with chronic hepatitis C infection who have initiated treatment. It is not the treatment rate among all infected people and it is not a cure-rate measure.
Are all values on the map from 2024?
No. Of 96 latest observations, 91 are from 2024. Brazil is from 2025, Australia, Canada and the Republic of Korea are from 2023, and Japan is from 2021. The 2024 distribution and rankings use only the 91 same-year rows.
Does 100% mean every person infected with hepatitis C has been treated?
No. A 100% value applies to the diagnosed chronic HCV population used as the denominator. People who remain undiagnosed are outside this indicator, and the measure does not by itself confirm treatment completion or cure.
Do gray countries on the map have a 0% treatment rate?
No. Gray indicates that no retained observation is present in this 96-row extract, or that a very small country does not appear as a distinct polygon in the low-resolution map. Missing values are not converted to zero.
Related Articles
These Green Map articles provide additional context on country-level health data and access-related indicators.
- Tanzania 2022 TDHS-MIS Guide – Demographic, Health and Malaria Survey
- Global Clean Cooking Access Map – 2023 Country Comparison
- Rural Basic Drinking Water Access Map – Latest Country Data
Green Map creates custom-edited map images using open geographic data sources such as geoBoundaries, Natural Earth, OpenStreetMap, and government open data.
These maps are edited visual materials, not raw data files, and are provided for education, documents, presentations, and graphic reference.
